Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.

Saved in:
Bibliographic Details
Title: Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
Authors: Jyssum I; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Kared H; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Tran TT; Department of Immunology, Oslo University Hospital, Oslo, Norway., Tveter AT; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Provan SA; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Sexton J; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Jørgensen KK; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway., Jahnsen J; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway., Kro GB; Department of Microbiology, Oslo University Hospital, Oslo, Norway., Warren DJ; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway., Vaage EB; Department of Immunology, Oslo University Hospital, Oslo, Norway., Kvien TK; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Nissen-Meyer LH; Department of Immunology, Oslo University Hospital, Oslo, Norway., Anderson AM; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Grødeland G; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Haavardsholm EA; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Vaage JT; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Mjaaland S; Norwegian Institute of Public Health, Oslo, Norway., Syversen SW; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Lund-Johansen F; ImmunoLingo Convergence Center, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Munthe LA; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Goll GL; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
Source: The Lancet. Rheumatology [Lancet Rheumatol] 2022 Mar; Vol. 4 (3), pp. e177-e187. Date of Electronic Publication: 2021 Dec 23.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2665-9913
DOI:10.1016/S2665-9913(21)00394-5